Othman Bin-Alamer, Hussam Abou-Al-Shaar, Selcuk Peker, Yavuz Samanci, Isabelle Pelcher, Sabrina Begley, Anuj Goenka, Michael Schulder, Jean-Nicolas Tourigny, David Mathieu, Andréanne Hamel, Robert G Briggs, Cheng Yu, Gabriel Zada, Steven L Giannotta, Herwin Speckter, Sarai Palque, Manjul Tripathi, Saurabh Kumar, Rupinder Kaur, Narendra Kumar, Brandon Rogowski, Matthew J Shepard, Bryan A Johnson, Daniel M Trifiletti, Ronald E Warnick, Samantha Dayawansa, Elad Mashiach, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Zane Schnurman, Juan Alzate, Douglas Kondziolka, Jason P Sheehan
{"title":"前庭许旺瘤 Koos II 级主动监测与立体定向放射外科手术的国际研究:VISAS-K2 研究","authors":"Othman Bin-Alamer, Hussam Abou-Al-Shaar, Selcuk Peker, Yavuz Samanci, Isabelle Pelcher, Sabrina Begley, Anuj Goenka, Michael Schulder, Jean-Nicolas Tourigny, David Mathieu, Andréanne Hamel, Robert G Briggs, Cheng Yu, Gabriel Zada, Steven L Giannotta, Herwin Speckter, Sarai Palque, Manjul Tripathi, Saurabh Kumar, Rupinder Kaur, Narendra Kumar, Brandon Rogowski, Matthew J Shepard, Bryan A Johnson, Daniel M Trifiletti, Ronald E Warnick, Samantha Dayawansa, Elad Mashiach, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Zane Schnurman, Juan Alzate, Douglas Kondziolka, Jason P Sheehan","doi":"10.1227/neu.0000000000003216","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS).</p><p><strong>Methods: </strong>A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes.</p><p><strong>Results: </strong>A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively (P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04).</p><p><strong>Conclusion: </strong>For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study.\",\"authors\":\"Othman Bin-Alamer, Hussam Abou-Al-Shaar, Selcuk Peker, Yavuz Samanci, Isabelle Pelcher, Sabrina Begley, Anuj Goenka, Michael Schulder, Jean-Nicolas Tourigny, David Mathieu, Andréanne Hamel, Robert G Briggs, Cheng Yu, Gabriel Zada, Steven L Giannotta, Herwin Speckter, Sarai Palque, Manjul Tripathi, Saurabh Kumar, Rupinder Kaur, Narendra Kumar, Brandon Rogowski, Matthew J Shepard, Bryan A Johnson, Daniel M Trifiletti, Ronald E Warnick, Samantha Dayawansa, Elad Mashiach, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Zane Schnurman, Juan Alzate, Douglas Kondziolka, Jason P Sheehan\",\"doi\":\"10.1227/neu.0000000000003216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS).</p><p><strong>Methods: </strong>A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes.</p><p><strong>Results: </strong>A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively (P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04).</p><p><strong>Conclusion: </strong>For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.</p>\",\"PeriodicalId\":19276,\"journal\":{\"name\":\"Neurosurgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1227/neu.0000000000003216\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003216","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:本研究评估了立体定向放射外科手术(SRS)与观察等待治疗 Koos II 级前庭神经分裂瘤(VS)的疗效和安全性:进行了一项多中心回顾性分析,主要针对接受 SRS(SRS 组)或观察(观察组)的 Koos II 级 VS 患者。为确保组间的可比性,采用了倾向评分匹配法,包括人口统计学特征、肿瘤尺寸和听力评估等因素。研究的主要终点是肿瘤控制、听力维持和神经系统结果:两个队列中共有 92 名患者匹配度相同,SRS 组的中位随访时间为 37 个月,观察组的中位随访时间为 27.5 个月。在3年、5年和8年的随访中,SRS组的肿瘤控制率优于观察组,达到100%,而观察组在这些时间间隔内的肿瘤控制率分别为47.9%、40.1%和34.3%(P < .001)。在 3 年、5 年和 7 年期间,两组的听力保存率相当(3 年时,SRS 为 72.9% ,观察组为 65.4%;P = .86)。此外,SRS 治疗与较低的前庭症状发生率相关(几率比 = 0.11,P = .002),在颅神经 (CN) V 或 CN VII 功能恶化方面没有明显差异。值得注意的是,SRS 组群中出现任何 CN 功能障碍的可能性显著降低(几率比 = 0.47,P = .04):结论:对于 Koos II 级 VS 患者,SRS 可提供更高的肿瘤控制率和更低的 CN 功能障碍风险,同时不会牺牲听力的保护。
Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study.
Background and objectives: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS).
Methods: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes.
Results: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively (P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04).
Conclusion: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
期刊介绍:
Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery.
Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.